Axxcess Wealth Management LLC Sells 3,413 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Axxcess Wealth Management LLC lowered its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 16.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 16,802 shares of the company’s stock after selling 3,413 shares during the period. Axxcess Wealth Management LLC’s holdings in Intellia Therapeutics were worth $196,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently made changes to their positions in NTLA. KBC Group NV increased its stake in shares of Intellia Therapeutics by 37.3% during the third quarter. KBC Group NV now owns 3,753 shares of the company’s stock worth $77,000 after purchasing an additional 1,020 shares during the period. Quest Partners LLC increased its stake in shares of Intellia Therapeutics by 181.6% during the third quarter. Quest Partners LLC now owns 19,748 shares of the company’s stock worth $406,000 after purchasing an additional 12,734 shares during the period. Jennison Associates LLC increased its stake in shares of Intellia Therapeutics by 21.6% during the third quarter. Jennison Associates LLC now owns 47,899 shares of the company’s stock worth $984,000 after purchasing an additional 8,497 shares during the period. Intech Investment Management LLC bought a new position in shares of Intellia Therapeutics during the third quarter worth approximately $580,000. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Intellia Therapeutics by 4.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 827,545 shares of the company’s stock worth $17,006,000 after purchasing an additional 37,714 shares during the period. Institutional investors own 88.77% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on NTLA shares. StockNews.com upgraded Intellia Therapeutics to a “sell” rating in a research note on Monday, March 3rd. Truist Financial lowered their price objective on Intellia Therapeutics from $90.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday, March 4th. Oppenheimer lowered their price objective on Intellia Therapeutics from $60.00 to $40.00 and set an “outperform” rating on the stock in a research note on Monday, January 13th. BMO Capital Markets lowered their price objective on Intellia Therapeutics from $70.00 to $50.00 and set an “outperform” rating on the stock in a research note on Friday, January 10th. Finally, Citigroup raised their price objective on Intellia Therapeutics from $12.00 to $14.00 and gave the stock a “neutral” rating in a research note on Friday, February 28th. Two research analysts have rated the stock with a sell rating, six have given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Intellia Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $37.56.

Insider Activity at Intellia Therapeutics

In related news, CEO John M. Leonard sold 26,807 shares of the firm’s stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total transaction of $326,509.26. Following the sale, the chief executive officer now owns 941,115 shares of the company’s stock, valued at $11,462,780.70. This trade represents a 2.77 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders have sold a total of 29,000 shares of company stock valued at $352,551 in the last 90 days. 3.20% of the stock is owned by corporate insiders.

Intellia Therapeutics Stock Up 3.4 %

NASDAQ NTLA opened at $9.00 on Friday. Intellia Therapeutics, Inc. has a twelve month low of $8.30 and a twelve month high of $28.23. The company has a market cap of $931.65 million, a price-to-earnings ratio of -1.65 and a beta of 1.97. The business’s fifty day moving average is $10.09 and its 200 day moving average is $14.18.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.